Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/13/2012 | 10:15am CET
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVO NORDISK A/S
01/21 Agenda Released for Pharmaceutical Freeze Drying 2017 Summit Featuring Pfizer..
01/20 CLASS PERIOD EXPANDED IN CLASS ACTION LAWSUIT – Brower Piven Encourages..
01/20 NOVO NORDISK A/S : Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Clas..
01/20 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Novo Nordisk ..
01/16 LAWSUIT FOR INVESTORS WHO LOST MONEY : Nvo)
01/16 NOVO NORDISK A/S : - Share repurchase programme
01/13 Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against No..
01/12 NOVO NORDISK A/S : An Application for the Trademark "SOLVE" Has Been Filed by No..
01/12 NOVO NORDISK A/S : Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Clas..
01/12 REPORTS ON GLUCAGON THERAPY FROM NOV : Chemical...
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 Implications Of The Latest Smash In Bristol-Myers Squibb Stock
01/20 NEKTAR THERAPEUTICS : An Undervalued Biopharmaceuticals Company With Plenty In T..
01/19 NOVO NORDISK : Key Threats In 2017 And Beyond
01/19 ONE STEP CLOSER TO FINANCIAL FREEDOM : My 2016 Income Review
01/18 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2016 Update
Advertisement
Financials ( DKK)
Sales 2016 111 861 M
EBIT 2016 48 780 M
Net income 2016 38 082 M
Finance 2016 14 309 M
Yield 2016 2,86%
P/E ratio 2016 16,55
P/E ratio 2017 15,61
EV / Sales 2016 4,35x
EV / Sales 2017 4,15x
Capitalization 500 726 M
More Financials
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 281  DKK
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-2.32%72 057
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results